Stefano Tamburin (Italy)

University of Verona Department of Neurosciences, Biomedicine and Movement Sciences
Stefano Tamburin, MD, PhD is Associate Professor of Neurology at the University of Verona, Italy. His main clinical and research interests include neurodegenerative disorders (Parkinson’s disease, Alzheimer’s disease, dementia), peripheral nervous system diseases, neuropathic pain, central and peripheral neurotoxicity to chemotherapy for cancer, with an integrative and translational approach that encompasses clinical evaluation, instrumental tools (neurophysiological techniques, imaging, psychophysics), rehabilitation and applied technology for the treatment of the patients.He published more than 170 peer-reviewed articles. He is associate editor for Frontiers in Neurology and Medicine and member of the editorial board of other international peer-reviewed journals.

Author Of 1 Presentation

 Conference Calendar
Free Communication

3T MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND THALAMOTOMY IN PATIENTS WITH ESSENTIAL TREMOR: THREE-YEAR CLINICAL EXPERIENCE FROM A SINGLE CENTER

Session Type
Free Communication
Session Name
200 - FREE COMMUNICATION: Movement Disorders (ID 142)
Date
03.10.2021, Sunday
Session Time
11:30 - 13:00
Room
Free Communication B
Lecture Time
12:30 - 12:40
Presenter
  • Stefano Tamburin (Italy)

Abstract

Background and Aims:

Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy of the ventralis intermedius (Vim) nucleus is emerging as a minimally invasive treatment for patients with disabling and medication-refractory essential tremor (ET). We report our preliminary three-year experience on 52 patients with ET treated from January 2018 to December 2020 in a single center.

Methods:

From January 2018 to December 2020, 52 patients (31 men, 21 women, age: 73.5 ± 7.8 years) underwent MRgFUS thalamotomy of the Vim nucleus for disabling and refractory ET (tremor duration: 22.6 ± 12.1 years) with a 3T magnetic resonance scanner at Verona University Hospital.

Results:

At baseline the total Clinical Rating Scale for Tremor (CRST) score was 45.8 ± 15.6, and the Quality of Life in Essential Tremor Questionnaire (QUEST) score was 40.8 ± 13.8. At one-month follow-up, the total CRST score was 12.8 ± 6.3 and the QUEST score was 10.5 ± 4.1. Response persisted in the majority of patients at three-month, six-month, one-year, two-year and three-year follow-up. Side effects related to Vim nucleus thalamotomy included ataxia, speech disorder, ballism, paresthesia, and lower limb hypasthenia and were mild and transitory in most patients.

Conclusions:

Our data confirm that MRgFUS thalamotomy of the Vim nucleus is an effective and safe treatment for disabling and refractory ET and its effects are long-lasting.

Hide

Presenter of 1 Presentation

 Conference Calendar
Free Communication

3T MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND THALAMOTOMY IN PATIENTS WITH ESSENTIAL TREMOR: THREE-YEAR CLINICAL EXPERIENCE FROM A SINGLE CENTER

Session Type
Free Communication
Session Name
200 - FREE COMMUNICATION: Movement Disorders (ID 142)
Date
03.10.2021, Sunday
Session Time
11:30 - 13:00
Room
Free Communication B
Lecture Time
12:30 - 12:40
Presenter
  • Stefano Tamburin (Italy)

Abstract

Background and Aims:

Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy of the ventralis intermedius (Vim) nucleus is emerging as a minimally invasive treatment for patients with disabling and medication-refractory essential tremor (ET). We report our preliminary three-year experience on 52 patients with ET treated from January 2018 to December 2020 in a single center.

Methods:

From January 2018 to December 2020, 52 patients (31 men, 21 women, age: 73.5 ± 7.8 years) underwent MRgFUS thalamotomy of the Vim nucleus for disabling and refractory ET (tremor duration: 22.6 ± 12.1 years) with a 3T magnetic resonance scanner at Verona University Hospital.

Results:

At baseline the total Clinical Rating Scale for Tremor (CRST) score was 45.8 ± 15.6, and the Quality of Life in Essential Tremor Questionnaire (QUEST) score was 40.8 ± 13.8. At one-month follow-up, the total CRST score was 12.8 ± 6.3 and the QUEST score was 10.5 ± 4.1. Response persisted in the majority of patients at three-month, six-month, one-year, two-year and three-year follow-up. Side effects related to Vim nucleus thalamotomy included ataxia, speech disorder, ballism, paresthesia, and lower limb hypasthenia and were mild and transitory in most patients.

Conclusions:

Our data confirm that MRgFUS thalamotomy of the Vim nucleus is an effective and safe treatment for disabling and refractory ET and its effects are long-lasting.

Hide